Add 2.27 mL BAC water
Specific targeting of deubiquitylating enzymes or E3 ubiquitin ligase enzymes that are involved in well-characterized disease processes will enable the development of specific new treatment options in renal disease
K.DainiakN
The blots were incubated with the following primary antibodies: GAPDH (1:10,000, Proteintech, 60,0041-Ig), HK2 (1:1000, Abcam, ab209847), TH (1:5000, Abcam, ab137869), LDHA (1:1000, Cell Signaling Technology, 3582S), Bax (1:1000, Abcam, ab32503), Bcl2 (1:1000, Abcam, ab32124), AMPK1/2 (H 300) (1:500, Santa Cruz Biotechnology, sc-25,792), phospho-AMPK1/2 (Thr 183/172) (1:500, Santa Cruz Biotechnology, sc-101,630), phospho-Akt (Thr308) (1:1000, Cell Signaling Technology, 4056S), Akt (1:1000, Cell Signaling Technology, 9272S), phospho-mTOR (Ser2448) (1:1,000, Cell Signaling Technology, 5336S), mTOR (7C10) (1:1000, Cell Signaling Technology, 2983S), -Synuclein (1:1000, Cell Signaling Technology, 4179S), BDNF (1:1000, Abcam, ab108319), PGC-1 (1:100, Abcam, ab191838), PDK1 (1:2000, Abcam, ab202468), PKM2 (1:1000, Cell Signaling Technology, 4053), GPX4 (1:1000, Abcam, ab125066), UCP2 (1:1000, Abcam, 89326), ATP5A (1:1000, Cell Signaling Technology, 18023), UQCRC2 (1:1000, Cell Signaling Technology, 99258), MTCO1 (1:1000, Abcam, ab14705), SIRT1 (1:1000, Abcam, ab110304), HIF-1 (1:1000, Abcam, ab308433), NRF1 (1:1000, Abcam, ab175932), and NRF2 (1:1000, Abcam, ab207223)
